AAV gene therapy is essentially one-shot. After the first dose, the immune system generates neutralizing antibodies (NAbs) against the viral capsid. These NAbs persist for years thanks to memory B cells. A second dose of the same serotype gets neutralized before it reaches target cells.
This is not a hypothetical concern. Patients seropositive for anti-AAV antibodies are excluded from most clinical trials. And 30-60% of the general population already has pre-existing anti-AAV immunity from childhood wild-type AAV exposure.
For STRC gene therapy, this creates a specific problem. If the first dose does not achieve sufficient transduction, there is no second chance with the same vector. This is where the delivery vehicle choice becomes critical.
Neutralizing antibody titer over time after intracochlear AAV administration (seronegative patient). Cochlear immune privilege reduces systemic response by ~30% compared to IV delivery.
Percentage of population with pre-existing neutralizing antibodies by AAV serotype:
Pediatric (<5 years): 20-30% (lower than adults)
Boutin et al. 2010, Calcedo et al. 2015
| Property | AAV | LNP | Exosome |
|---|---|---|---|
| First-dose efficiency | 60-90% | 10-50% | 5-20% |
| Immune response | Strong: IgG NAbs + memory B cells | Innate only (complement). No memory | Minimal (autologous) |
| Re-dosing | Extremely difficult (same serotype) | Every 2-4 weeks | Anytime |
| Seroprevalence barrier | 30-60% excluded | 0% | 0% |
| Cochlear advantage | Partial immune privilege | Repeatable compensates lower per-dose | Natural barrier crossing |
| Clinical readiness | Phase 1/2 (for OTOF) | Preclinical (cochlear), approved (COVID) | Early research |
Single-vector mini-STRC has a higher probability of success on the first (and possibly only) AAV dose. Dual-vector full STRC wastes half the dose on each vector, then loses another 70-80% to failed recombination.
The hybrid strategy from our delivery model (AAV surgery for base coverage + LNP top-up via sonoporation) directly addresses the re-dosing problem. AAV provides high initial transduction. LNP provides indefinite maintenance doses without immune barrier.
For pediatric patients like Misha (age 4), anti-AAV seroprevalence is lower (20-30%). This is a timing advantage that diminishes with age as children encounter wild-type AAV.
Cochlear immune privilege is real but incomplete. The blood-perilymph barrier is weaker than the blood-brain barrier. Local AAV delivery to the cochlea generates lower systemic NAb responses than intravenous delivery, but still sufficient to block re-dosing with the same serotype. The 30% reduction factor is estimated from comparative studies of intraocular vs systemic AAV delivery in NHPs (Timmers 2022). Direct cochlear NAb kinetics data in humans does not yet exist.